Showing 181 - 200 results of 10,646 for search '(( 50 μ decrease ) OR ( 50 ((((nn decrease) OR (mean decrease))) OR (we decrease)) ))', query time: 0.43s Refine Results
  1. 181
  2. 182
  3. 183
  4. 184
  5. 185
  6. 186
  7. 187
  8. 188
  9. 189
  10. 190

    Parthenolide Derivatives as PKM2 Activators Showing Potential in Colorectal Cancer by Xingchen Liu (524190)

    Published 2021
    “…As a vital kinase in the glycolysis system, PKM2 is extensively expressed in colorectal cancer (CRC) to support the energy and biosynthetic needs. In this study, we designed a series of parthenolide (PTL) derivatives through a stepwise structure optimization, and an excellent derivate <b>29e</b> showed good activity on PKM2 (AC<sub>50</sub> = 86.29 nM) and displayed significant antiproliferative activity against HT29 (IC<sub>50</sub> = 0.66 μM) and SW480 (IC<sub>50</sub> = 0.22 μM) cells. …”
  11. 191

    Parthenolide Derivatives as PKM2 Activators Showing Potential in Colorectal Cancer by Xingchen Liu (524190)

    Published 2021
    “…As a vital kinase in the glycolysis system, PKM2 is extensively expressed in colorectal cancer (CRC) to support the energy and biosynthetic needs. In this study, we designed a series of parthenolide (PTL) derivatives through a stepwise structure optimization, and an excellent derivate <b>29e</b> showed good activity on PKM2 (AC<sub>50</sub> = 86.29 nM) and displayed significant antiproliferative activity against HT29 (IC<sub>50</sub> = 0.66 μM) and SW480 (IC<sub>50</sub> = 0.22 μM) cells. …”
  12. 192

    Parthenolide Derivatives as PKM2 Activators Showing Potential in Colorectal Cancer by Xingchen Liu (524190)

    Published 2021
    “…As a vital kinase in the glycolysis system, PKM2 is extensively expressed in colorectal cancer (CRC) to support the energy and biosynthetic needs. In this study, we designed a series of parthenolide (PTL) derivatives through a stepwise structure optimization, and an excellent derivate <b>29e</b> showed good activity on PKM2 (AC<sub>50</sub> = 86.29 nM) and displayed significant antiproliferative activity against HT29 (IC<sub>50</sub> = 0.66 μM) and SW480 (IC<sub>50</sub> = 0.22 μM) cells. …”
  13. 193

    Parthenolide Derivatives as PKM2 Activators Showing Potential in Colorectal Cancer by Xingchen Liu (524190)

    Published 2021
    “…As a vital kinase in the glycolysis system, PKM2 is extensively expressed in colorectal cancer (CRC) to support the energy and biosynthetic needs. In this study, we designed a series of parthenolide (PTL) derivatives through a stepwise structure optimization, and an excellent derivate <b>29e</b> showed good activity on PKM2 (AC<sub>50</sub> = 86.29 nM) and displayed significant antiproliferative activity against HT29 (IC<sub>50</sub> = 0.66 μM) and SW480 (IC<sub>50</sub> = 0.22 μM) cells. …”
  14. 194

    Parthenolide Derivatives as PKM2 Activators Showing Potential in Colorectal Cancer by Xingchen Liu (524190)

    Published 2021
    “…As a vital kinase in the glycolysis system, PKM2 is extensively expressed in colorectal cancer (CRC) to support the energy and biosynthetic needs. In this study, we designed a series of parthenolide (PTL) derivatives through a stepwise structure optimization, and an excellent derivate <b>29e</b> showed good activity on PKM2 (AC<sub>50</sub> = 86.29 nM) and displayed significant antiproliferative activity against HT29 (IC<sub>50</sub> = 0.66 μM) and SW480 (IC<sub>50</sub> = 0.22 μM) cells. …”
  15. 195
  16. 196
  17. 197

    Temporal profiles of the key BO-NN features. by Julia Berezutskaya (9080269)

    Published 2020
    “…Right plot show the gradual decrease in the TM tuning for the features highlighted in <b>c</b> as well as the gradual increase in the temporal response profile (i.e. optimal shifts for the prediction of the key BO-NN features using Praat features shown in <b>a</b>). …”
  18. 198
  19. 199
  20. 200